Dermira (NASDAQ:DERM) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research downgraded shares of Dermira (NASDAQ:DERM) from a strong-buy rating to a hold rating in a research report report published on Tuesday morning, Zacks.com reports.

According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “

Several other research firms have also issued reports on DERM. Mizuho upgraded shares of Dermira from a neutral rating to a buy rating and dropped their target price for the company from $17.00 to $14.00 in a report on Thursday, June 6th. Cantor Fitzgerald reiterated a buy rating and set a $25.00 price objective on shares of Dermira in a report on Friday, May 3rd. BidaskClub upgraded shares of Dermira from a sell rating to a hold rating in a report on Friday, August 9th. Finally, HC Wainwright reiterated a buy rating on shares of Dermira in a report on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. Dermira currently has a consensus rating of Buy and an average target price of $17.72.



NASDAQ DERM opened at $8.54 on Tuesday. The business’s fifty day moving average is $8.65. The company has a market capitalization of $458.05 million, a PE ratio of -1.63 and a beta of 1.33. Dermira has a fifty-two week low of $6.00 and a fifty-two week high of $15.48. The company has a current ratio of 8.42, a quick ratio of 8.08 and a debt-to-equity ratio of 4.95.

Dermira (NASDAQ:DERM) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.57. The firm had revenue of $66.65 million for the quarter, compared to analysts’ expectations of $34.16 million. Dermira had a negative net margin of 306.91% and a negative return on equity of 478.29%. As a group, analysts expect that Dermira will post -4.94 EPS for the current year.

Large investors have recently bought and sold shares of the company. Eversept Partners LP lifted its stake in shares of Dermira by 122.8% during the 2nd quarter. Eversept Partners LP now owns 399,874 shares of the biopharmaceutical company’s stock valued at $3,823,000 after buying an additional 220,374 shares in the last quarter. Earnest Partners LLC lifted its stake in shares of Dermira by 7.7% during the 2nd quarter. Earnest Partners LLC now owns 586,560 shares of the biopharmaceutical company’s stock valued at $5,608,000 after buying an additional 42,060 shares in the last quarter. Sofinnova Investments Inc. lifted its stake in shares of Dermira by 36.4% during the 2nd quarter. Sofinnova Investments Inc. now owns 659,882 shares of the biopharmaceutical company’s stock valued at $6,309,000 after buying an additional 176,242 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Dermira by 8.5% during the 2nd quarter. Northern Trust Corp now owns 476,772 shares of the biopharmaceutical company’s stock valued at $4,557,000 after buying an additional 37,398 shares in the last quarter. Finally, Fosun International Ltd lifted its stake in shares of Dermira by 28.7% during the 2nd quarter. Fosun International Ltd now owns 425,626 shares of the biopharmaceutical company’s stock valued at $3,822,000 after buying an additional 95,000 shares in the last quarter. 93.42% of the stock is owned by institutional investors.

About Dermira

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Featured Article: How to Invest in a Bull Market

Get a free copy of the Zacks research report on Dermira (DERM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.